Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.59 |
| ▸ | UBE2M | P61081 | 1/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944257 | 0.88 | ALDH1A1 (0.66) | SIGMAR1ALDH1A1SMN1; SMN2KMT2APOLB | |
| SCHEMBL30089449 | 0.88 | ALDH1A1 (0.66) | SIGMAR1ALDH1A1SMN1; SMN2KMT2APOLB | |
| Trifluoroacetic Acid SCHEMBL1920766 | 0.84 | SIGMAR1 (0.53) | SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL1921350 | 0.81 | MCHR1 (0.58) | SIGMAR1FAAHKMT2AACHE | |
| SCHEMBL1519149 | 0.80 | SIGMAR1 (0.65) | SIGMAR1ALDH1A1SMN1; SMN2FAAHKMT2A | |
| SCHEMBL5360590 | 0.79 | SIGMAR1 (0.60) | SIGMAR1ALDH1A1SMN1; SMN2KMT2APOLB | |
| Trifluoroacetic Acid SCHEMBL1920595 | 0.79 | ARG1 (0.52) | SIGMAR1ALDH1A1KMT2AMEN1 | |
| Trifluoroacetic Acid SCHEMBL19613522 | 0.79 | DRD2 (0.49) | SIGMAR1ALDH1A1KMT2AACHEMEN1 | |
| Trifluoroacetic Acid SCHEMBL19613524 | 0.79 | DRD2 (0.49) | SIGMAR1ALDH1A1KMT2AACHEMEN1 | |
| SCHEMBL18658336 | 0.79 | SIGMAR1 (0.71) | SIGMAR1UBE2MDCUN1D1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | SIGMAR1 1187/4885UBE2M 4672/4885DCUN1D1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.